Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study

Abstract: Background: One-third of Veterans with major depressive disorder suffer from treatment-resistant depression (TRD). This is the first study to evaluate the long-term …

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study

Abstract: BACKGROUND: One-third of Veterans with major depressive disorder suffer from treatment-resistant depression (TRD). This is the first study to evaluate the long-term …

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – 12-month data from an open-label pilot study

Abstract: Background One-third of Veterans with major depressive disorder suffer from treatment-resistant depression (TRD). This is the first study to evaluate the long-term …

Ketamine-occasioned mystical experience in Veterans with treatment-resistant depression: A retrospective exploratory analysis

Abstract: Introductions: Mystical experiences are powerful experiences that may have therapeutic value. Ketamine, a dissociative anesthetic, has shown potential to induce mystical …

Research and implementation of psychedelic-assisted therapy in the Veterans Health Administration

Abstract: The article discusses the research and potential implementation of Psychedelic-Assisted Therapy (PAT) in the Veterans Health Administration (VA). It highlights the …

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study

Abstract: Background: The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates of suicide and disability. This is …

Ethical considerations for psychedelic-assisted therapy in military clinical settings

Abstract: Psychedelic treatments, particularly 3,4-methylenedioxymethamphetamine (MDMA)-assisted and psilocybin-assisted therapies, have recently seen renewed interest in their …